Related Experiment Video

Updated: Aug 5, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis

A Bitsch1, D Bahner, C Wachter

  • 1Neurologische Klinik, Ruppiner Kliniken GmbH, Neuruppin, Germany. a.bitsch@ruppiner-kliniken.de

Acta Neurologica Scandinavica
|November 6, 2004
PubMed

Insights

Interferon beta-1b (IFNB-1b) treatment increases soluble vascular cell adhesion molecule-1 (sVCAM-1) in primary progressive multiple sclerosis (PPMS) patients. This suggests IFNB-1b modulates endothelial activation in PPMS, similar to relapsing-remitting MS.

Area of Science:

  • Neuroimmunology
  • Vascular Biology
  • Multiple Sclerosis Pathogenesis

Background:

  • Endothelial activation is crucial in multiple sclerosis (MS) pathogenesis.
  • Interferon beta-1b (IFNB-1b) is known to modulate endothelial activation in relapsing-remitting MS (RRMS).
  • The effect of IFNB-1b on endothelial activation in primary progressive MS (PPMS) remains unproven.

Purpose of the Study:

  • To investigate the pharmacodynamic effects of IFNB-1b on endothelial activation markers in PPMS patients.
  • To analyze serum concentrations of soluble vascular cell adhesion molecule-1 (sVCAM-1) and sE-selectin during IFNB-1b treatment.

Main Methods:

  • Longitudinal analysis of serum sVCAM-1 and sE-selectin in 18 PPMS patients.
  • Measurements taken before, during, and after 12 months of IFNB-1b treatment.
  • Correlation analysis with flu-like symptoms, infections, and neutralizing antibodies to IFNB-1b.

Main Results:

  • A significant, early, and sustained increase in serum sVCAM-1 was observed during IFNB-1b therapy (P < 0.0001).
  • Higher sVCAM-1 levels were associated with IFNB-1b-induced flu-like symptoms and infections.
  • Lower sVCAM-1 levels correlated with the presence of neutralizing antibodies to IFNB-1b.

Conclusions:

  • IFNB-1b modulates the adhesion cascade in PPMS patients, mirroring effects seen in RRMS.
  • The findings suggest a similar pharmacodynamic action of IFNB-1b in both MS subtypes.
  • Further randomized controlled trials are necessary to establish the clinical efficacy of IFNB-1b in PPMS.

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-&#945;08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...